patiromer sorbitex calcium · Vifor Pharma · NDA 205739
Veltassa
Earliest generic entry, as listed · earliest of 3 marketed strengths
8 Oct 2033
Blocked by patent: US 11123363, US 9492476, US 9925212. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 7 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11123363 | use U-1766 | 8 Oct 2033 |
| US 9492476 | use U-1766 | 8 Oct 2033 |
| US 9925212 | use U-1766 | 8 Oct 2033 |
| US 8337824 | substance, use U-1766 | 29 May 2030 |
| US 8147873 | product | 20 Jun 2028 |
| US 8282913 | product | 29 May 2027 |
| US 8216560 | use U-1766 | 14 Mar 2027 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 4
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 205739 · 001 · RLD | powder, oral | EQ 8.4GM BASE/PACKET | 8 Oct 2033 |
| 205739 · 002 · RLD | powder, oral | EQ 16.8GM BASE/PACKET | 8 Oct 2033 |
| 205739 · 003 · RLD · discontinued | powder, oral | EQ 25.2GM BASE/PACKET | 8 Oct 2033 |
| 205739 · 004 · RLD | powder, oral | EQ 1GM BASE/PACKET | 8 Oct 2033 |
Expired or delisted (2)
- NPP · 2 Oct 2026
- NS · 2 Oct 2026